ArticleObesity surgery2014
Medication cost is significantly reduced after Roux-en-Y gastric bypass in obese patients.
Article in Obesity surgery, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Chinese Guidelines for Medical Nutrition Therapy for Patients with Diabetes (2022 Edition).Asia Pacific journal of clinical nutrition · 2024Article
- Comparison of pre-and postoperative medication costs in patients who underwent bariatric surgery - a nationwide data analysis.Frontiers in public health · 2024Article
- Cost effectiveness of bariatric surgery in patients with obesity related comorbidities: A retrospective study.Journal of family medicine and primary care · 2021Article
- Does bariatric surgery reduce future hospital costs? A propensity score-matched analysis using UK Biobank Study data.International journal of obesity (2005) · 2021Article
- Weight Loss After Sleeve Gastrectomy: Does Type 2 Diabetes Status Impact Weight and Body Composition Trajectories?Obesity surgery · 2021Article
- Association of Roux-en-Y Gastric Bypass With Postoperative Health Care Use and Expenditures in Canada.JAMA surgery · 2020Article
- The Role of Bariatric Surgery on Diabetes and Diabetic Care Compliance.Current diabetes reports · 2019Review
- Changes in Body Composition, Comorbidities, and Nutritional Status Associated with Lower Weight Loss After Bariatric Surgery in Older Subjects.Obesity surgery · 2019Article
- Reduced Need for In-hospital Care After Sleeve Gastrectomy: a Single Center Observational Study.Obesity surgery · 2019Observational
- Effect of Roux-en-Y gastric bypass on pharmacologic dependence in obese patients with type 2 diabetesCanadian journal of surgery. Journal canadien de chirurgie · 2019Article
- Estimated Costs of Clinical and Surgical Treatment of Severe Obesity in the Brazilian Public Health System.Obesity surgery · 2017Observational
- The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: A multi-center study.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · 2017Article
- Is Bariatric Surgery Effective in Reducing Comorbidities and Drug Costs?: Letter to the editor.Obesity surgery · 2016Article
- Micronutrient and Protein Deficiencies After Gastric Bypass and Sleeve Gastrectomy: a 1-year Follow-up.Obesity surgery · 2016Article
- Is Bariatric Surgery Effective in Reducing Comorbidities and Drug Costs? Reply to Letter to the Editor.Obesity surgery · 2016Article
- Nutritional and Protein Deficiencies in the Short Term following Both Gastric Bypass and Gastric Banding.PloS one · 2016Article
- Barriers in the Approach of Obese Patients Undergoing Bariatric Surgery in Flemish Hospitals.Obesity surgery · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aims to determine the influence of Roux-en-Y gastric bypass (RYGB) on medication-related costs.
methodsThe study analyzed the types, dosages, and costs of drugs and medical devices prescribed before and after surgery (1, 3, 6, and 12 months and yearly thereafter) in patients who underwent RYGB between June 2004 and May 2010 and had an outpatient visit between December 2009 and May 2010 at Pitié-Salpêtrière University Hospital, Paris, France.
resultsThe cohort included 143 patients (78 % female; mean age, 42.9 years; mean BMI, 48.6 kg/m(2)). Total prescription costs were significantly lower (-32 %, p < 0.001) 1 year after RYGB compared with preoperative costs. However, the cost for medications to prevent RYGB side effects (in particular nutritional deficiencies) displayed a 36-fold increase in the first month postsurgery, but then decreased progressively over time. Importantly, the cost related to the treatment of the two most frequent obesity-related diseases significantly decreased 1 year after surgery. Indeed, prescription costs for treatment of type 2 diabetes (T2D) and obstructive sleep apnea (OSA) (namely CPAP therapy considered as the gold standard treatment) were reduced 1 year after surgery by 85 and by 63 % (both p < 0.001), respectively. We also observed a trend toward a decrease in the prescription costs of other obesity-related diseases, although it did not reach significance in our cohort.
conclusionsConsidering medication to treat both obesity-related diseases and prevention of secondary effects of bariatric surgery, we observed that overall postoperative medication costs were significantly reduced one year after surgery, especially for T2D and OSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.